NCT07275242 is a Phase 1 clinical trial of SHR-A1811 Subcutaneous Injection in Solid Tumor, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd..

Who is sponsoring NCT07275242?

NCT07275242 is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd..

What drugs are being tested in NCT07275242?

Interventions in NCT07275242: SHR-A1811 Subcutaneous Injection, SHR-A1811 for Injection.

What condition does NCT07275242 study?

NCT07275242 studies Solid Tumor.

Is NCT07275242 still recruiting?

NCT07275242 is currently recruiting now. Last updated 13 January 2026.

Last reviewed 2026-01-13 · How we verify

NCT07275242

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-Label, Multi-site Phase I Clinical Study of SHR-A1811(sc) Subcutaneous Injection: Evaluating Pharmacokinetics, Safety, Tolerability, and Efficacy in Patients With Solid Tumor

Recruiting now Phase 1 Last updated 13 January 2026

What this trial tests

Phase 1 trial testing SHR-A1811 Subcutaneous Injection in Solid Tumor in 107 participants. Currently enrolling.

Timeline

23 December 2025

Primary endpoint
1 June 2027

1 December 2027

Quick facts

Lead sponsor	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	107
Start date	23 December 2025
Primary completion	1 June 2027
Estimated completion	1 December 2027
Sites	1 location across China

Drugs / interventions tested

SHR-A1811 Subcutaneous Injection — full drug profile →
SHR-A1811 for Injection — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Area under the curve from time zero to 21 days (AUC0-21d) of SHR-A1811(sc)
Time frame: About 72 weeks.
The incidence and severity of Dose-Limiting Toxicities (DLTs)
Time frame: About 72 weeks.
Adverse Events (AEs)
Time frame: About 72 weeks.

Sponsor's own description

The study is being conducted to evaluate the pharmacokinetics , safety, tolerability and efficacy in patients with solid tumor.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other Suzhou Suncadia Biopharmaceuticals Co., Ltd. trials

Trials by the same sponsor.

NCT06844474 — A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC · Phase 2 · recruiting
NCT06703177 — A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06643754 — A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors · Phase 1, PHASE2 · recruiting
NCT06618651 — A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors · Phase 1 · recruiting
NCT06640257 — A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07275242 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Last refreshed: 13 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07275242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing